poly adenyl ribose polymerase PARP Inhibitors - Biotech, Pharma and Life Science Channel
Poly (ADP-ribose) polymerases (PARPs) are a family of nuclear enzymes implicated in the regulation of multiple physiological cellular functions, including DNA repair, gene transcription, protein modification and cell signaling. Over-activation of PARP results in pathologic alteration of cellular metabolism, activation of inflammatory pathways, perturbation of cellular energetics, and cell death through necrosis or apoptosis. Because of its involvement in DNA repair, PARP has been implicated in the development of anti-tumor drug resistance. Targeting PARP is an approach in solid tumor therapy for potentiating the effects of chemotherapy and of radiation therapy and for potentially reducing antitumor drug resistance or resensitizing resistant patients to antitumor therapies. The most advanced projects are in phase II studies of solid tumors.
News Articles
SEATTLE, June 17, 2013 /PRNewswire/ -- Cell Therapeutics, Inc. (CTI) (NASDAQ and MTA: CTIC) today announced results from a pooled analysis of data from completed Phase 1 and 2 studies of pacriti...
Enanta Pharmaceuticals to Present at the Wells Fargo Securities 2013 Healthcare Conference
Enanta Pharmaceuticals, Inc., (NASDAQ: ENTA), a research and development-focused biotechnology company dedicated to creating small molecule drugs in the infectious disease field,...
The European Medicines Agency’s Pharmacovigilance Risk Assessment Committee (PRAC) has concluded that the effects of the painkiller diclofenac on the heart and circulation when given systemically (b...
Medivir Recruits a New Head of Commercial Operations
Regulatory News: Medivir AB (OMX: MVIR) (STO:MVIR-B) strengthens the executive management team by recruiting Henrik Krook as Executive VP Commercial. Henrik will b...
NORCROSS, Ga., June 12, 2013 /PRNewswire-USNewswire/ -- Galectin Therapeutics (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, today an...
rEVO Biologics, an LFB Company, announced today that it has completed the treatment and follow up phase of a key dose ranging study of LR769, a novel recombinant form of hu...
The Angeles Clinic and Research Institute presented groundbreaking new data on “Clinical Activity, Safety and Biomarkers of MPDL3280A, an Engineered PD-L1 Antibody in Pat...
NEW YORK, June 6, 2013 /PRNewswire/ -- Editor Note: For more information about this release, please scroll to bottom. Today, Wall Street Reports announced new research reports highlighting Clovis On...
DOYLESTOWN, Pa., June 5, 2013 /PRNewswire/ -- Novira Therapeutics Inc., today announced the expansion of its senior management team with the appointment of Klaus Klumpp, Ph.D., as vice president,...
Move Over Rodents, Enter Robots
BROOKLYN, N.Y., June 5, 2013 /PRNewswire/ -- Rats and mice have long been a model for researchers aiming to understand the complex impact of alcohol and other substances of abuse on behavior and...
Events
Diabetes: Secondary Complications, Regulation and Innovation Conference
SMi is very proud to present our 11th conference focusing on Diabetes and metabolic disorders taking place on 1st and 2nd Oct 2013, London.
Companies
The Angeles Clinic and Research Institute
âThe Angeles Clinic and Research Instituteâs mission is to advance cancer care through groundbreaking research and delivering innovative therapeutic options to al...
DOV is a biopharmaceutical company historically focused on the development of novel product candidates for disorders of the central nervous system. DOV has previously funded drug development and disco...
Onconova, based in Newtown, PA and Lawrenceville, NJ, discovers and develops novel patent- protected small molecule therapeutic agents for cancer, radiation protection and hematol...
Enanta Phatmaceuticals ARE A RESEARCH AND DEVELOPMENT-FOCUSED BIOTECHNOLOGY COMPANY that uses its robust chemistry-driven approach and drug discovery capabilities to create small molecule drugs in t...
NeurAxon, Inc. (www.neuraxon.com) discovers and develops next-generation pain therapeutics focused on its first-in-class selective inhibitors of neuronal nitric oxide synthase...
Founded in 2001, AB Science is a pharmaceutical company specialising in the research, development and commercialisation of protein kinase inhibitors (PKIs), a new class of targete...
Sagene Pharmaceuticals is a biopharmaceutical company developing novel applications for combinations of FDA-approved drugs to treat diseases associated with aging. Sagene h...
Tensha Therapeutics is developing small molecule bromodomain inhibitors, a new class of epigenetic modulators of gene expression, to treat cancer and other serious disorders. The...
Genkyotex is developing first in class, small molecule therapeutics that specifically and selectively inhibit the NOX family of enzymes. Using a unique screening platform, Genkyot...
Angion Biomedica is a biopharmaceutical company founded in 1998 focused on discovery and development of drugs that harness the bodyâs protective, reparative and regenerative...
Clinical Trials
The purpose of this research study is to: 1) Determine the highest dose of the drug vorinostat that can be given safely in combination with carboplatin and gemcitabine and 2) determine how...
Pilot Trial to Assess Effect of CNI Conversion of Efalizumab on T Reg Cells
The purpose of this pilot trial is to determine whether a conversion from calcineurin inhibitors (CNI) and mycophenolate mofetil (MMF) to a regimen consisting of efalizumab and sirolimus i...
89Zr-trastuzumab PET for Imaging the Effect of HSP90 Inhibition
HSP90 inhibition is a potentially new targeted drug modality in the treatment of HER2 positive, trastuzumab refractory breast cancer. Little is known about the pharmacodynamics of HSP90 in...
RATIONALE: Aromatase inhibitors, such as letrozole, prevent the formation of estradiol, a female hormone. Giving letrozole together with goserelin, leuprolide, or surgery may be an effecti...
This randomized phase II trial is studying how well giving tacrolimus and mycophenolate mofetil (MMF) together with or without sirolimus works in preventing acute graft-versus-host disease...
Characterization of Receptors in Non-functioning Pituitary Macroadenomas
Characterization of receptors present in non-functioning pituitary macroadenomas by Reverse Transcriptase- Polymerase Chain Reaction (RT-PCR) would assist with targeted medical therapy bas...
Imatinib Mesylate in Combination With Docetaxel for Advanced, Platinum-Refractory Ovarian Cancer
Imatinib mesylate is an inhibitor of the receptor tyrosine kinases for platelet-derived growth factor (PDGF) and stem cell factor (SCF), c-Kit, and inhibits PDGF- and SCF-mediated cellular...
This is a prospective study of surgically resected samples and lymph nodes of lung cancer patients. For histopathologically positive lymph nodes from a complete resection, the investigator...
A Study Of Nasopharyngeal Carcinoma (NPC) Treated With Celecoxib And ZD1839
EGFR and COX-2 are involved in tumorigenesis, angiogenesis and metastases and are frequently over expressed in NPC.COX-2 and EGFR inhibitors are active in NPC.There is synergistic action b...
The Effects of Anabolic Steroids and Protease Inhibitors on People Living With HIV/AIDS
The main aim of the study is to investigate the combined effects of using anabolic steroids and protease inhibitors on fat metabolism and body composition of People Living with HIV/AIDS....
PubMed Articles
Caspase (CASP) 3, 8, 9 are important caspases in the apoptosis pathway and play important roles in development and progression of cancer. A case-control study with 451 colorectal cancer (CRC) patients...
Elevated SGK1 predicts resistance of breast cancer cells to Akt inhibitors.
The majority of human cancers harbour mutations promoting activation of the Akt protein kinase, and Akt inhibitors are being evaluated in clinical trials. An important question concerns the understand...
The title compound, [K(C14H23)(C4H8O)]n, comprises zigzag chains of alternating bridging 2,3,4,5-tetramethyl-1-n-pentylcyclopentadienyl ligands and potassium ions, with an ancillary tetrahydrofuran li...
Engagement of NKG2D and DNAX accessory molecule-1 (DNAM-1) receptors on lymphocytes plays an important role for anticancer response and represents an interesting therapeutic target for pharmacological...
Potent, reversible inhibition of the cytochrome P450 CYP2C9 isoform was observed in a series of urea-containing nicotinamide phosphoribosyltransferase (NAMPT) inhibitors. This unwanted property was su...
A novel series of indole/indazole-aminopyrimidines was designed and synthesized with an aim to achieve optimal potency and selectivity for the c-Jun kinase family or JNKs. Structure guided design was...
1-(1,3,5-Triazin-yl)piperidine-4-carboxamide inhibitors of soluble epoxide hydrolase were identified from high through-put screening using encoded library technology. The triazine heterocycle proved t...
Discovery of TAK-960: An orally available small molecule inhibitor of polo-like kinase 1 (PLK1).
Using structure-based drug design, we identified and optimized a novel series of pyrimidodiazepinone PLK1 inhibitors resulting in the selection of the development candidate TAK-960. TAK-960 is current...
Discovery of new potent inhibitors for carbonic anhydrase IX by structure-based virtual screening.
Through structure-based virtual screening, some dozen of benzene sulfonamides with novel scaffolds are identified as potent inhibitors against carbonic anhydrase (CA) IX with IC50 values ranging from...
The synthesis and structure-activity relationships of a novel aryl uracil series which contains a fused 5,6-bicyclic ring unit for HCV NS5B inhibition is described. Several analogs display replicon ce...
Videos
Medical and Biotech [MESH] Definitions
Taxodium
A plant genus of the family TAXODIACEAE. Members contain taxodione and taxodone, which are diterpenoid quinone methide tumor inhibitors.
Huperzia
A plant genus of the family LYCOPODIACEAE. Members contain huperzine, one of the CHOLINESTERASE INHIBITORS.
Host Factor 1 Protein
An integration host factor that was originally identified as a bacterial protein required for the integration of bacteriophage Q beta (ALLOLEVIVIRUS). Its cellular function may be to regulate mRNA stability and processing in that it binds tightly to poly(A) RNA and interferes with ribosome binding.
Tata-box Binding Protein
A general transcription factor that plays a major role in the activation of eukaryotic genes transcribed by RNA POLYMERASES. It binds specifically to the TATA BOX promoter element, which lies close to the position of transcription initiation in RNA transcribed by RNA POLYMERASE II. Although considered a principal component of TRANSCRIPTION FACTOR TFIID it also takes part in general transcription factor complexes involved in RNA POLYMERASE I and RNA POLYMERASE III transcription.
Transcription Factor Tfiiib
One of several general transcription factors that are specific for RNA POLYMERASE III. TFIIIB recruits and positions pol III over the initiation site and remains stably bound to the DNA through multiple rounds of re-initiation by RNA POLYMERASE III.
